Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal
Journal of Clinical Medicine · 18.04.2023 · 12 (8) · 2933
DOI: 10.3390/jcm12082933 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 18.04.2023. Verfasst von Rafael Pelayo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Sciences, Stanford University Sleep Medicine Center, Redwood City, CA 94063, USA. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Idorsia Pharmaceuticals US, Inc. (Idorsia), Idorsia, LAS Communications, Inc..
Themen: Schlaf
Abstract (Originalsprache)
Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as a first-line treatment for insomnia, with the focus statement “Trazodone should never be used as a first-line medication for insomnia.” In addition, field surveys were sent to practicing physicians, psychiatrists, and sleep specialists to assess general support for this statement. Subsequently, a meeting with a seven-member panel of key opinion leaders was held to discuss published evidence in support and against the statement. This paper reports on the evidence review, the panel discussion, and the panel’s and healthcare professionals’ ratings of the statement’s acceptability. While the majority of field survey responders disagreed with the statement, the majority of panel members agreed with the statement based on the limited published evidence supporting trazodone as a first-line agent as they understood the term “first-line agent”.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Sciences, Stanford University Sleep Medicine Center, Redwood City, CA 94063, USA.
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Psychology, Cervo Brain Research Centre, Laval University, Quebec, QC G1E 1T2, Canada.
- Department of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
- Department of Neurology, Center for Circadian and Sleep Medicine, Northwestern University, Evanston, IL 60611, USA.
- Departments of Psychiatry and Neurology, UCSF Weill Institute for Neurosciences, San Francisco, CA 94158, USA.
ORCID-Profile: Rafael Pelayo, Suzanne M Bertisch, Phyllis C Zee
Förderung
- Idorsia Pharmaceuticals US, Inc. (Idorsia)
- Idorsia
- LAS Communications, Inc.
Zitieren
APA
Pelayo, R., Bertisch, S. M., Morin, C. M., Winkelman, J. W., Zee, P. C., & Krystal, A. D. (2023). Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal. Journal of Clinical Medicine, 12(8), 2933. https://doi.org/10.3390/jcm12082933
Vancouver
Pelayo R, Bertisch SM, Morin CM, Winkelman JW, Zee PC, Krystal AD. Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal. Journal of Clinical Medicine. 2023;12(8):2933. doi:10.3390/jcm12082933
BibTeX
@article{Pelayo2023,
author = {Pelayo, Rafael and Bertisch, Suzanne M and Morin, Charles M and Winkelman, John W and Zee, Phyllis C and Krystal, Andrew D},
title = {Should Trazodone Be First-Line Therapy for Insomnia? A Clinical Suitability Appraisal},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {8},
pages = {2933},
doi = {10.3390/jcm12082933}
}
EUVIMED